Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05614349 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings

Study acronym: CanTreatCOVID
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: estimated 10000 to confirmed 797 Trial status: Recruiting to Active, Not Recruiting · Primary completion date changed from estimate of Mar 31, 2026 to Apr 28, 2025 · Completion date: Mar 31, 2026 to Jun 28, 2025 · 5 morev6 Show 8 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Mar 31, 2026 to Apr 28, 2025
    • Completion date: Mar 31, 2026 to Jun 28, 2025
    • Interventions: Other (Drug), Other (Other), Paxlovid (Drug) to Antioxidant (Drug), Paxlovid (Drug)
    • Eligibility criteria expanded, about 152 words
    • Secondary endpoints revised (6)
    • Site details revised at 6 of 6 sites
    • Study arms: 4 to 3

    See this version in full on ClinicalTrials.gov ↗

  2. Site contacts updated at 6 of 6 sitesv5
  3. Primary completion date: Jan 2024 to Mar 31, 2026 Primary endpoints: 2 to 1 · Enrollment target: 12000 to 10000 · Study sites: 3 to 6 · 3 morev4 Show 6 more changesShow less
    • Primary endpoints: 2 to 1
    • Enrollment target: 12000 to 10000
    • Study sites: 3 to 6
    • Completion date: Jan 2025 to Mar 31, 2026
    • Secondary endpoints: 5 to 6
    • Collaborators reordered

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 1 to 3v3
  5. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Dec 2023 to Jan 2024 · Completion date: Dec 2024 to Jan 2025 · Start date changed from estimate of Dec 2022 to Jan 16, 2023 · 3 morev2 Show 6 more changesShow less
    • Primary completion date: Dec 2023 to Jan 2024
    • Completion date: Dec 2024 to Jan 2025
    • Start date changed from estimate of Dec 2022 to Jan 16, 2023
    • Secondary endpoints: 6 to 5
    • Site details revised
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
CanTreatCOVID is an open-label, individually randomized, multi-centre, national trial. CanTreatCOVID aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for SARS-CoV-2 for non-hospitalized patients in Canada. Participants will be randomized to receive usual care (i.e. supportive care and symptom relief) or a study therapeutic, which will be determined by the Canadian COVID-19 Out-Patient Therapeutics Committee. The primary outcomes being evaluated is hospitalization and/or death at 28 days, as well as time to recovery.
Trial Details
NCT Number NCT05614349
Lead Sponsor Unity Health Toronto
Collaborators: Health Canada, Canadian Institutes of Health Research (CIHR)
Conditions COVID-19
Enrollment 797 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov